Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.

Bibliographische Detailangaben
Hauptverfasser:	Pellagatti, A, Jadersten, M, Forsblom, A, Cattan, H, Christensson, B, Emanuelsson, E, Merup, M, Nilsson, L, Samuelsson, J, Sander, B, Wainscoat, J, Boultwood, J, Hellstrom-Lindberg, E
Format:	Conference item
Veröffentlicht:	2006

Ähnliche Einträge

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
von: Pellagatti, A, et al.
Veröffentlicht: (2007)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
von: Jadersten, M, et al.
Veröffentlicht: (2005)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
von: Jädersten, M, et al.
Veröffentlicht: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
von: Scharenberg, C, et al.
Veröffentlicht: (2011)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
von: Pellagatti, A, et al.
Veröffentlicht: (2009)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes
von: Pellagatti, A, et al.
Veröffentlicht: (2007)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
von: Pellagatti, A, et al.
Veröffentlicht: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
von: Pellagatti, A, et al.
Veröffentlicht: (2010)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
von: Pellagatti, A, et al.
Veröffentlicht: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
von: Pellagatti, A, et al.
Veröffentlicht: (2011)

Gene expression profiling in the myelodysplastic syndromes.
von: Pellagatti, A, et al.
Veröffentlicht: (2005)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
von: Pellagatti, A, et al.
Veröffentlicht: (2009)

Clonality in the myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (2001)

Molecular pathogenesis of the myelodysplastic syndromes
von: Boultwood, J, et al.
Veröffentlicht: (1999)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
von: Pellagatti, A, et al.
Veröffentlicht: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
von: Pellagatti, A, et al.
Veröffentlicht: (2010)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
von: Nikpour, M, et al.
Veröffentlicht: (2007)

INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES
von: Ballabio, E, et al.
Veröffentlicht: (2010)

Telomere length in myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (1995)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
von: Lewis, S, et al.
Veröffentlicht: (1995)

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
von: Pellagatti, A, et al.
Veröffentlicht: (2013)

Molecular diagnosis of the 5q deletion in malignant myeloid disorders.
von: Boultwood, J
Veröffentlicht: (1996)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
von: Boultwood, J, et al.
Veröffentlicht: (2010)

Hematologic malignancies : myelodysplastic syndromes /
von: Deeg, H. Joachim (Hans Joachim), 1945-
Veröffentlicht: (2006)

SF3B1 mutant myelodysplastic syndrome: Recent advances
von: Pellagatti, A, et al.
Veröffentlicht: (2020)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
von: Pellagatti, A, et al.
Veröffentlicht: (2008)

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE IN MYELODYSPLASTIC SYNDROMES - REPLY
von: Boultwood, J, et al.
Veröffentlicht: (1991)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
von: Pellagatti, A, et al.
Veröffentlicht: (2016)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
von: Pellagatti, A, et al.
Veröffentlicht: (2006)

Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders
von: Zhang, J, et al.
Veröffentlicht: (2004)

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
von: Boultwood, J, et al.
Veröffentlicht: (2007)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
von: Boultwood, J, et al.
Veröffentlicht: (2009)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (2014)

COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
von: Pellagatti, A, et al.
Veröffentlicht: (2014)

Gene silencing by DNA methylation in haematological malignancies.
von: Boultwood, J, et al.
Veröffentlicht: (2007)

Progression in patients with low- and intermediate1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
von: Scharenberg, C, et al.
Veröffentlicht: (2016)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
von: Malcovati, L, et al.
Veröffentlicht: (2011)

Telomere length in myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (1997)

Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
von: Watkins, F, et al.
Veröffentlicht: (2004)

Mutation analysis of the SPARC gene in the 5q-syndrome.
von: Fidler, C, et al.
Veröffentlicht: (2000)